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Mutations of the c-kit gene have been reported in myeloproliferative disorders. We describe here
a case of Phþ (b2a2) chronic myelogenous leukemia that, during the course of disease, showed
an unusual bone marrow mast-cell infiltration. A mutational screening for the c-kit gene,
performed on DNA routinely cryopreserved during the follow-up, evidenced the D816Y-
activating mutation as an additional genetic abnormality. Treatment with imatinib mesylate
resulted in a substantial decrease of the BCR-ABL/ABL ratio and in the absence of c-kit
mutation. It is likely that the superimposed c-kit mutation, in this case, may account for the
transient bone marrow mastocytosis.
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Introduction
Mutations in the proto-oncogene c-kit (the receptor for
c-kit ligand, also known as stem cell factor and mast-cell
growth factor) at the level of a pluripotential hemo-
poietic progenitor cell have been implicated in the
pathogenesis of mast-cell disorders.1 Furthermore, it
is well recognized that activating mutations of the
c-kit gene on chromosome 4 are also found in
myeloproliferative disorders (MPD).2–4 In a study of
25 patients with MPD, Kimura and Nakata found point
mutations in exon 2 of the c-kit extracellular domain,
leading to D52N substitution in one patient with
chronic myelogenous leukemia (CML) and two patients
with primary myelofibrosis (PMF). The authors
postulated that this mutation might affect the tertiary
SCF-binding site or the efficiency of ligand-induced
dimerization of the receptor leading to the enhancement
of the receptor kinase activity of the intracellular
domain. In addition, the D52N substitution resulted in
apparently higher sensitivity of erythroid progenitor to
SCF.2,3 Using RT-PCR Inokuchi et al.4 studied 80
patients with CML in various clinical phases and
identified sequence alterations in the c-kit juxtamem-
brane domain in seven cases. The authors concluded
that these mutations led to leukocytosis (Po0.05) and
to shorter survival (P¼ 0.04) of CML patients.4
Furthermore, it is well known that there is a significant
increase of c-kit protein and c-kit m-RNA level in CML
when compared with healthy volunteers, and this
expression correlates with the phase of disease, being
highest in the blast crisis of CML.5
Case report
In the following, we describe the case of a Philadelphia-
positive CML patient who, during the course of the
disease, showed an unusual bone marrow MC infiltra-
tion and, as an additional genetic change, a D816Y
mutation in exon 17 of the c-kit gene. The patient, a 36-
year-old male, was referred to our department 5 years
after the diagnosis of CML. Upon physical examination,
an enlarged liver (4 cm below the costal margin) and a
palpable spleen (1 cm below the costal margin) was
noted. His white blood cell (WBC) count was 24 109/l
with 62% neutrophils, 19% lymphocytes, 12% mono-
cytes, 1% myelocytes, 1% metamyelocytes and 1%
promyelocytes; the hemoglobin concentration was
16 g/dl and platelet count was 2540 109/l. A bone
marrow aspirate was consistent with a CML in chronic
phase and cytogenetic analysis revealed a 46 XY,
t(9;22)(q34;q11) [20] karyotype. We initially treated the
patient with ARA-C 400mg/day PO and a-IFN
5MU/day and then with a-IFN alone. The treatment
with a-IFN resulted only in a minimal cytogenetic
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response as the number of Ph-negative metaphases
reached only 8%. After 12 months of a-IFN treatment,
the WBC count was 18 109/l, the bone marrow
aspirate and biopsy were still consistent with a CP of
CML and, for the first time, an unusual MC infiltration
was noted; cytogenetics showed a t(9;22)(q34;q11)[35]
karyotype and the real-time quantitative PCR evidenced
a b2a2 chimeric transcript with a BCR-ABL/ABL ratio
of 0.13.6 It is worth noting that clinical signs consistent
with an hystamine excess (ie urticarian rashes, flushing,
gastrointestinal disorders evocative of peptic ulcer,
diarrhea or hypotension) were absent, ruling out the
association of hematological disease to a pre-existing
condition of sporadic mastocytosis. Once the a-IFN
resistance was documented, a treatment with imatinib
mesylate at a dose of 400mg/day was started.7 At
evaluation 6 and 12 months after imatinib mesylate
initiation, cytogenetics showed a 46 XY[20] karyotype
with a BCR-ABL/ABL ratio of 0.003 and 0.001,
respectively.
The presence of the bone marrow mastocytosis led us
to perform a screening for the c-kit gene as previously
described.8,9 The mutational analysis was performed on
DNA extracted from viable bone marrow cell routinely
cryopreserved at regular intervals during the follow-up.
Four samples were studied: 4 months before the starting
of imatinib mesylate therapy, at the time of the imatinib
initiation and 6–12 months thereafter. The screening
showed the D816Y mutation only in the bone marrow
collected just before the start of imatinib mesylate
administration when cytogenetics evidenced t(9;22)
(q34;q11)[35] karyotype, and the BCR-ABL/ABL ratio
was 0.13. A careful examination of the bone marrow
aspirate and biopsy, specifically addressed to detect
marrow mastocytosis, was carried out, allowing us to
assess a direct relationship between the presence of the
D816Y mutation and the presence of MC in the bone
marrow (Figure 1). Furthermore, no marrow hypereo-
sinophilia was detected. In conclusion, our PCR data,
carried out sequentially during the follow-up, clearly
demonstrate that the D816Y mutation can occur in a
long-lasting CML clone as an additional genetic change.
The fact that the BCR/ABL rearrangement and the kit
mutation may coexist within the same cell is indirectly
demostrated by the findings that following imatinib
mesylate treatment, a substantial decrease of BCR-
ABL/ABL ratio and the absence of kit mutation could
be evidenced. It is likely that the mutated c-kit may add
a further growth advantage to the CML progenitor cells
driven to a sustained proliferation by the high TK
activity of the BCR-ABL gene product. Finally, the
superimposed kit mutation may account for the
transient bone marrow mastocytosis, which indicates
the capability of the leukemic progenitor cells to
differentiate into the MC lineage.
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chronic phase: 4 months before starting of imatinib therapy (a), at the
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